Home / Resource Library / HIGH EFFICACY AND FAVORABLE SAFETY OF CD20-TARGETED CAR-T THERAPY FOR BTK INHIBITOR-REFRACTORY WALDENSTROM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL)
HIGH EFFICACY AND FAVORABLE SAFETY OF CD20-TARGETED CAR-T THERAPY FOR BTK INHIBITOR-REFRACTORY WALDENSTROM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL)